I-Mab Announces Upcoming Participation at July Conference

SHANGHAI and GAITHERSBURG,Md.,June 29,2021 -- I-Mab (the "Company") (Nasdaq: IMAB),a clinical stage biopharmaceutical company committed to the discovery,development and commercialization of novel biologics,today announced its participation in the following conference in July. Details of the conference are as follow:

CMBI Healthcare Corporate Day (Virtual)

Management participants: Dr. Jingwu Zang,Founder,Chairman and Director,Dr. Joan Huaqiong Shen,Director and Chief Executive Officer,Mr. Jielun Zhu,Director and Chief Financial Officer,and Mr. Tianyi Zhang,Executive Director Investor Relations

One-on-one and small group meetings: July 7-9,2021

For more information,please contact your CMBI representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery,development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships,based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities,a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters),Beijing,Hangzhou and Hong Kong in China,and Maryland and San Diego in the United States. For more information,please visithttp://ir.i-mabbiopharma.comand follow I-Mab onLinkedIn,TwitterandWeChat.

For more information,please contact:

I-Mab

Jielun Zhu,Chief Financial Officer

E-mail:jielun.zhu@i-mabbiopharma.com

Office line: +86 21 6057 8000

Gigi Feng,Chief Communications Officer

E-mail:gigi.feng@i-mabbiopharma.com

Office line: +86 21 6057 5709

Investor Inquiries:

The Piacente Group,Inc.

Emilie Wu

E-mail:emilie@thepiacentegroup.com

Office line: +86 21 6039 8363

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-july-conference-301321723.html